Hints and tips:
Related Special Reports
...Despite Novo Nordisk and Eli Lilly’s lead, Steensberg believed there was space for others to develop weight-loss products....
...Eli Lilly and Vertex declined to comment on the talks....
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...US drug regulators have delayed a decision on whether to approve Eli Lilly’s breakthrough Alzheimer’s drug, which was expected to be greenlit this month, the drugmaker said on Friday....
...Patients on the donanemab study had more advanced Alzheimer’s than patients on similar studies, Eli Lilly said....
...But that is what Eli Lilly did this week....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...It is also unlikely that Eli Lilly will provide enough doses of the drug to Britain to meet the demand for weight loss treatments....
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...Eli Lilly’s share price fell as much as 2.4 per cent in early US trading before later recovering its losses....
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
...“The obesity field is going to be dominated by those two guys [Novo Nordisk and Eli Lilly] and who wants to go up against them?” he said. “It would be super hard.”...
...Eli Lilly’s $12.50 a share cash offer for Point represents a 50 per cent premium to the stock’s undisturbed three month average....
International Edition